LY2334737-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemELY2334737Cat. No.: HY-13672CAS No.: 892128-60-8分式: CHFNO分量: 389.39作靶点: Nucleoside Antimetabolite/Analog作通路: Cell Cycle/DNA Damage储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (2

2、56.81 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.5681 mL 12.8406 mL 25.6812 mL5 mM 0.5136 mL 2.5681 mL 5.1362 mL10 mM 0.2568 mL 1.2841 mL 2.5681 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果

3、的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.42 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (6.42 mM); Clear solution3. 请依序添加每种溶剂： 10% DMSO 90% cor

4、n oil1/2 Master of Small Molecules 您边的抑制剂师www.MedChemESolubility: 2.5 mg/mL (6.42 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 LY2334737服活性的gemcitabine原药。REFERENCES1. Pratt SE, et al. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancercel

5、ls. Clin Cancer Res. 2013 Mar 1;19(5):1159-68.2. Koolen SL, et al. Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients withadvanced solid tumors. Clin Cancer Res. 2011 Sep 15;17(18):6071-82.3. Francia G, et al. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence ofinhibition of systemic vasculogenesis. Mol Cancer Ther. 2012 Mar;11(3):680-9.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3